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Abstract
Molecular signatures in Glioblastoma (GBM) have been described that correlate
with clinical outcome and response to therapy. The Proneural (PN) and
Mesenchymal (MES) signatures have been identified most consistently, but others
including Classical (CLAS) have also been reported. The molecular signatures
have been detected by array techniques at RNA and DNA level, but these methods
are costly and cannot take into account individual contributions of different cells
within a tumor. Therefore, the aim of this study was to investigate whether
subclasses of newly diagnosed GBMs could be assessed and assigned by
application of standard pathology laboratory procedures. 123 newly diagnosed
GBMs were analyzed for the tumor cell expression of 23 pre-identified proteins and
EGFR amplification, together allowing for the subclassification of 65% of the
tumors. Immunohistochemistry (IHC)-based profiling was found to be analogous to
transcription-based profiling using a 9-gene transcriptional signature for PN and
MES subclasses. Based on these data a novel, minimal IHC-based scheme for
subclass assignment for GBMs is proposed. Positive staining for IDH1R132H can be
used for PN subclass assignment, high EGFR expression for the CLAS subtype
and a combined high expression of PTEN, VIM and/or YKL40 for the MES
subclass. The application of the proposed scheme was evaluated in an
independent tumor set, which resulted in similar subclass assignment rates as
those observed in the training set. The IHC-based subclassification scheme
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proposed in this study therefore could provide very useful in future studies for
stratification of individual patient samples.
Introduction
Glioblastoma (GBM) is the most frequent and aggressive primary brain tumor in
adults with a 5-year survival rate of less than 10% [1–3]. Standard treatment
comprises resection of the majority of tumor mass, followed by radio-
chemotherapy [3, 4]. The uniformly poor prognosis for all GBM patients merits
improvements in treatment. To better understand GBM biology, several groups
have therefore turned to high-dimensional profiling studies over the last decade.
These studies were performed in large GBM patient cohorts and have identified a
variety of GBM subclasses; the number of subclasses and their more precise
defining features are, however, still under debate [5–8]. The Proneural (PN) and
Mesenchymal (MES) subclasses have been identified most consistently and these
signatures were applied to approximately 30% and 30 to 50% of GBMs,
respectively [5, 6]. The PN subclass is characterized by mutations in isocitrate
dehydrogenase 1 (IDH1), and frequent alterations in expression of tumor protein
p53 (p53) and platelet-derived growth factor receptor, alpha polypeptide
(PDGFR-a) [6], whereas the MES subclass is characterized by mesenchymal gene
expression, of which CD44 and chitinase 3-like 1 (YKL40) are strong indicators
[5, 6, 9, 10]. Other subclasses such as Classical (CLAS), Neural (N) and
Proliferative (P) have also been proposed. The CLAS subgroup is characterized by
alterations in the epidermal growth factor receptor (EGFR), and the N subclass by
expression of neuronal markers. The P subclass shows high expression of
proliferative markers like proliferating cell nuclear antigen (PCNA) and
topoisomerase II alpha (TOP2A) [5, 6]. Many of the differential expression
patterns are reflective of alterations in chromosomes 7, 9 and 10, and these
alterations have been shown to have prognostic value in itself as well [11–14]. In
this study we focus however only on the more easily accessible protein expression
levels.
The clinical correlation of these molecular signatures has been subject of
investigation in two cross-sectional studies on archival GBM material [5, 6]. One
of these studies reported significantly better survival by the PN group, and they
described the MES group as the poorest prognosis group [5], whereas another
study only identified a trend towards better survival for the PN group [6]. The
latter study also described better response to more intensive therapy by the CLAS
and MES group, whereas this was not observed for the PN group. To identify
novel types of therapy targeting alterations specific for molecular subclasses it will
be important to implement molecular subclassification in future clinical trials.
An advantage of subclassification at protein level is that it does not require
additional types of tissue processing than those already performed for normal
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diagnostic procedures. In addition, high-throughput techniques are costly and less
feasible for individual patients in daily practice, thereby hindering inclusion of
molecular subtyping in laboratory and clinical studies. Therefore, this study was
set up to evaluate the possibility of subtyping by immunohistochemistry (IHC)
and fluorescence in situ hybridization (FISH) on formalin-fixed paraffin-
embedded (FFPE) GBM tissue. To assess this, a selection of 123 newly diagnosed
GBM cases was analyzed for the expression of 23 pre-identified proteins and
EGFR amplification on a tissue microarray (TMA). Next, unsupervised
hierarchical clustering was performed to identify groups of tumors with similar
expression patterns. Then, to relate the newly identified IHC/FISH-based
molecular profiles to previously described transcriptional profiles, tumors
representative of the PN or MES IHC/FISH-based profiles were assessed for a 9-
gene PN/MES-transcriptional signature [15]. Ultimately this study proposes a
novel scheme for IHC-based subclass assignment, which is evaluated in an
independent GBM tumor set. This novel scheme can be applied for the individual
patient sample using only a small selection of antibodies.
Materials and Methods
Patient population
Tissue samples were collected of adult patients that had received a diagnosis of
GBM (World Health Organization Grade IV astrocytoma) from November 2005
to July 2012 at our institution (department of Pathology, University Medical
Center Groningen, Netherlands). The patient selection was limited to newly
diagnosed GBMs. Tumors with radiological evidence of a less malignant precursor
lesion, so-called secondary or progressive GBMs, were excluded from the study.
Patients who underwent neurosurgical debulking and of which sufficient paraffin-
embedded archival tumor material was left after diagnosis were eligible for the
study. Finally, tumor tissue of 123 patients was included. The mean patient age at
diagnosis in the study group was 60 years (range 23–80; Table 1) and a two-third
overlap (70% of patients) was noted with the expected peak incidence age group
of primary GBM (45 to 70 years) [16].
Additionally, an independent validation tumor set consisting of 44 patients was
assembled following the same eligibility criteria as were applied for the training
set, but these patients were diagnosed with GBM from August 2012 to January
2014 at our institution. The mean patient age in this tumor group was 62 (range
32–84, Table 1), which also had a substantial overlap (77% of patients) with the
peak incidence age group of primary GBM.
All experiments including the use of human tissue were conducted under the
‘Code of Conduct for dealing responsibly with human tissue in the context of
health research’ published by the Federation of Dutch Medical Scientific Societies
in 2011 [17]. The human tissue used in this study was originally obtained for
diagnostic purposes and the scientific research performed on the leftover material
is considered to be ‘further use’ of the tissue. The authors had no interaction with
IHC-Based Subclassification of Newly Diagnosed GBMs
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the participants and all samples were anonymized before the authors obtained
them. Research on coded-anonymous human tissues is deemed acceptable under
an augmented system of opt-out when no specific circumstances apply, and
therefore approval was not required for this study.
Tissue microarray (TMA)
Sections from the original FFPE tissue blocks of the surgical debulkings were
stained with H&E and reviewed by a neuropathologist (WdD) to allow for
selection of vital tumor areas, after which biopsies were punctured from these
sites. From all tumors 4 biopsies of a 0.6 mm diameter were incorporated in the
TMAs and positive control tissue was also added directly in the TMAs. This
control tissue concerned samples from cortex, white matter, cerebellum, colon,
endometrial, kidney, liver, and spleen. The control tissue was used as a technical
reference in the evaluation of the staining patterns of the markers applied in this
study. Paraffin sections of 3 mm thickness were prepared for immunostaining and
5 mm sections for FISH.
Selection of markers specific of GBM subclasses
The selection of potential markers of interest for IHC/FISH-based subclassifica-
tion of GBM, was started with the markers from Phillips’ and Verhaak’s
classification of GBMs [5, 6]. This collection of markers was narrowed down by
selecting those markers for which experience with GBM IHC-analysis was
previously reported. Additionally, markers assessed in separate papers for which
relevance for subclassification of GBMs was suggested were also included.
Together this resulted in a final selection of 23 GBM subclass-associated markers
suitable for IHC analysis and a single FISH marker.
Immunofluorescence (IF) staining
Delta-like 3 (DLL3) expression was assessed by IF staining [9]. Endogenous
peroxidase of deparaffinized GBM tissue on TMAs was blocked using routine
techniques. The tissues were blocked for 30 minutes with 3% normal rabbit serum
in 1% BSA/PBS and then incubated with anti-DLL3 (diluted 1:200 in 1% BSA/
PBS; S1 Table) for 1 hour at room temperature (RT). The tissues were then
incubated for 30 minutes at RT with peroxidase-conjugated rabbit anti-goat
Table 1. Summary of characteristics of patients with newly diagnosed GBM in the training and validation tumor set.
Characteristic Training tumor set Validation tumor set
Number of patients 123 44
Mean age at diagnosis (range) 60 (23–80) 62 (32–84)
Male sex (%) 73 (59) 26 (59)
Female sex (%) 50 (41) 18 (41)
doi:10.1371/journal.pone.0115687.t001
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serum (DAKO, Glostrup, Denmark) diluted 1:100 in 1% BSA/PBS. The final
incubation step was one hour at RT with donkey anti-rabbit fluorescently labeled
antibody (Alexa fluor 647, Invitrogen, Karlsruhe, Germany) diluted 1:200 in 1%
BSA/PBS. Nuclear counterstaining by DAPI (diluted 1:1000) was added to the
mounting medium (Fluorescence Mouting Medium, DAKO).
IHC
Deparaffinized GBM tissue on TMAs was used to evaluate the expression of
several proteins. Antigen retrieval methods specified per antibody are listed in S1
Table. Endogenous peroxidase was blocked using 0.3% H2O2 for 30 minutes at
RT. The tissues were then incubated with a primary antibody at RT for 1 hour,
followed by application of a secondary antibody (peroxidase-conjugated serum,
DAKO), and a tertiary antibody (peroxidase-conjugated serum, DAKO), each for
30 minutes at RT. Antibody details of the primary antibodies used in this study
are listed in S1 Table. The secondary and tertiary antibodies were diluted 1:100 in
1% BSA/PBS with 1% AB serum. Color development was performed with 3,39-
diaminobenzidine for 10 minutes, and tissues were counterstained with
haematoxylin for 2 minutes.
Histological evaluation
Exclusively tumor cells were evaluated for the expression of proteins. The scoring
method was tailored to the observed staining pattern for individual markers,
thereby leading to six different semi-quantitative scoring schemes for the IHC
evaluation. Representative micrographs of the scoring patterns applied to each
individual staining are depicted in S1 and S2 Figs.
Markers reflecting genetic alterations (EGFRvIII, and IDH1 R132H mutation
[IDH1R132H]) were scored as either 05 ‘‘no alteration’’, or 15 ‘‘altered’’. Also the
EGFR pattern was evaluated best by scoring as either 0, no expression, or 1,
corresponding to diffuse high expression. A single score was assigned to each
tumor for IDH1R132H and EGFR based on all 4 cores as the expression of these
markers was consistent in each of the cores within a tumor. For all other markers
described the final score given for a marker was the result of the average of the
four biological replicates.
For two markers (fox-1 homolog 3 [NeuN] and oligodendrocyte lineage
transcription factor 2 [OLIG2]) a previously suggested scoring system was applied
[9]. Briefly, scoring was performed in 4 categories per core to quantify the number
of tumor cells expressing the respective antigen (0: no expression; 1: ,10%
expression; 2: 10%–49% expression; 3: 50%–90%).
Markers that displayed complete negative cores, cores with mixed positive and
negative sites, and complete positive cores were scored as 0, 1 and 2, respectively
(chromogranin A [CHGA], fibronectin 1 [FN1], neurofilament light chain
[NEFL], p53, phosphatase and tensin homolog [PTEN], and vimentin [VIM]).
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For three markers (CD44, hepatocyte growth factor receptor [MET], and
synaptophysin [SYP]) an additional intermediate level was required, thus
resulting in a scoring scheme range from 0 to 3. The scores for these markers were
0 for a complete negative core, 1 for focal weak staining, 2 for diffuse weak
staining or focal intense staining, and 3 was assigned to diffuse intense staining.
Besides these expression patterns, there were also markers that did not show
complete negative expression (glial fibrillary acidic protein [GFAP], nestin [NES],
neurofibromin 1 [NF1], PDGFR-a, signal transducer and activator of transcrip-
tion 3 [STAT3], and YKL40). These markers were scored either 1, basal level
expression, or 2, diffuse intense expression of the marker.
Finally, the proliferation index of individual tumors was assessed by two
antibodies (Ki-67 and TOP2A). Overview pictures of histological slides were
scanned using a C9600 NanoZoomer (Hamamatsu Photonics KK, Hamamatsu
City, Japan) and analyzed using ImageScope software (Aperio, Vista, CA). Squares
were placed within the individual cores to delineate an area containing 100 tumor
cells at minimum. In this block the total number and the positively stained tumor
cells were counted, allowing for calculation of the positive fraction (proliferation
index).
FISH
Dual-probe FISH analysis was performed on 5 mm sections of the TMAs.
Standard laboratory procedures were applied, and for hybridization the Vysis
EGFR/CEP7 FISH Probes were used (Abbott Molecular, Des Plaines, IL). Briefly,
deparaffinized slides were prepared for probe hybridization, including a boiling
step, incubation with RNA’se A solution and 0.1% pepsin solution. After probe
hybridization the tissues were dehydrated, and nuclei were counterstained using
DAPI diluted 1:3000 in mounting medium (Vectashield, Vector Laboratories,
Burlingame, CA).
As there are currently no solid criteria for scoring of EGFR FISH in GBM
available, but suggestions have been postulated in a recent paper [18]. We adopted
these criteria, and shortly summarized, tumors were assigned a positive FISH
status when the ratio of EGFR to centromere (CEP7) signal was $2, and a
negative FISH status was assigned in events where the EGFR:CEP7 ratio was ,2.
Representative images are shown in S2 Fig.
Cluster analysis
Data were analyzed using Genesis v1.7.6 [19]. Prior to clustering the scoring range
of all markers was standardized, except for the markers that directly or indirectly
reflected genetic abnormalities (EGFR FISH, EGFRvIII, and IDH1R132H).
Hierarchical clustering was performed, using Kendall’s tau coefficient and
average-linkage as clustering method, and clustering was applied to both markers
and tumors.
IHC-Based Subclassification of Newly Diagnosed GBMs
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PN/MES index
A PN/MES index was calculated based on protein expression scores in a
comparable manner as was described previously [9]. The selected PN markers
were IDH1R132H and p53, and the MES markers were PTEN, VIM, and YKL40.
For each individual marker scoring was performed as described under histological
evaluation. The scores for IDH1R132H and p53 were recoded into scores ranging
from 0 to 1.5, and the MES scores were recoded into scores ranging from 0 to 1.
The PN and MES subtype specific markers were then added up to obtain a total
PN and MES score, both having a maximum total score of 3. Subsequently the
PN/MES index was calculated by subtraction of the MES total score from the PN
total score.
Quantitative Reverse Transcriptase-Polymerase Chain Reaction
(qRT-PCR)
RNA was purified from 20 FFPE GBM samples as described previously [20]. To
assess purity of tumor tissue in these archival samples, sections of 3 mm thickness
were prepared of all GBM samples, and stained with H&E. Purified RNA was
quantified using Nanodrop ND-1000 UV spectrophotometer (NanoDrop
Technologies, Wilmington, DE). The RNA samples were DNase treated using the
Ambion turbo DNA Free kit (Life Technologies, Bleiswijk, the Netherlands) to
remove contaminating genomic DNA, and thereafter RNA content was again
quantified using Nanodrop. RNA was reverse transcribed to single-stranded
cDNA using Superscript II reverse transcriptase (Invitrogen) and random
hexamer primers (Promega, Leiden, the Netherlands). The qRT-PCR was
performed in triplicate with the qPCR MasterMix Plus (Eurogentec, Maastricht,
the Netherlands), using an ABI7900HT real-time sequence detection system in
384-well reaction plates. The following assays, all TaqMan single-gene expression
assays (Applied Biosystems, Foster City, CA), were used: ASCL1
(Hs00269932_m1), CHI3L1 (Hs00609691_m1), DLL3 (Hs01085096_m1),
NCAM1 (Hs00941821_m1), OLIG2 (Hs00377820_m1), RPS27 (Hs01378332_g1),
SERPINE1 (Hs01126606_m1), TGFB1 (Hs00932747_m1), and TIMP1
(Hs00355335_g1). The qRT-PCR data were analyzed using SDS software version
2.2.2.
In order to determine the association of the IHC/FISH-based molecular profiles
identified in this study with previously described transcriptional profiles [5, 6], 20
patient samples characteristic of either the PN (n510) or the MES (n510)
subclass in the IHC/FISH-based analyses were evaluated by a qRT-PCR
fingerprint. In this analysis, RPS27 was used as reference gene; ASCL1, DLL3,
NCAM1, and OLIG2 were used as PN genes and CHI3L1, SERPINE1, TGFB1, and
TIMP1 as MES genes. The averaged CT-value of the reference gene was subtracted
from Ct-values of the genes of interest, resulting in normalized expression values
(DCt-values) for individual PN and MES genes.
Secondly, a metagene score was calculated to generate a comparative heatmap
[15]. By averaging the inverse of the DCt-values for the PN and MES genes,
IHC-Based Subclassification of Newly Diagnosed GBMs
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application of Z-score correction, and finally subtraction of the PN score from the
MES score, a metagene score was generated.
Statistical analysis
Differences between groups were determined by the Mann-Whitney U or Kruskal-
Wallis test using SPSS software version 20.0.02 (SPSS, Chicago). Significant
Kruskal-Wallis tests were followed up by post-hoc tests (Bonferroni corrected).
Correlations were calculated by Pearson’s r or Spearman’s rho. P-values ,0.05
were considered significant.
Results
Subclass-specific marker expression in newly diagnosed GBMs
The PN subclass was examined through antibodies specific for DLL3, IDH1R132H,
OLIG2, p53, and PDGFR-a. All PN markers, except DLL3, showed sufficient
differences in their staining pattern to allow semi-quantitative scoring (S1 and S2
Figs.). For that reason DLL3 was excluded from further protein expression
analyses in the present paper. The mutation specific antibody for IDH1R132H [21–
23], detecting a mutation frequently found in lower-grade gliomas [23–25],
generated an easily distinctive pattern in our sample of GBMs. A total of 6 of 123
tumors (5%) were found to be positive for the R132H mutation in IDH1.
Detectable p53-expression by IHC analysis was observed in 119 of 123 tumors
(97%), but diffuse high overexpression of p53 (indicative of mutation) was
observed in only 19 of 123 tumors (15%). Elevated PDGFR-a expression was
observed in 27 of 123 tumors (22%). Overall 43 of 123 tumors (35%) showed one
or more positive PN markers.
EGFR markers were included to represent the CLAS subtype [5, 6]. Expression
of EGFR and its constitutively active (mutant) form EGFRvIII were assessed by
IHC, while EGFR amplification was assessed through FISH. The expression level
of EGFR and EGFRvIII was for all tumors consistent in all cores. Out of 123, 51
tumors (41%) presented with elevated EGFR protein expression. EGFR
amplification was observed in 49 tumors (40%) and EGFRvIII expression was
observed in 24 of 123 tumors (20%). Substantial concordance of the EGFR-
positive tumors was with the EGFR amplification status (Spearman’s rho [SR]
50.765, P,0.01) and EGFRvIII expression (SR50.543, P,0.01), and also
between the EGFR amplification status and EGFRvIII expression (SR50.521,
P,0.01). The IHC analysis for EGFR identified 43 of the 49 tumors in which
EGFR amplification was observed. Among these double positive tumors for EGFR
protein expression and gene amplification were 23 of the total 24 tumors in which
EGFRvIII expression was identified.
The MES subclass was assessed through expression of the markers CD44, FN1,
NES, NF1, STAT3, VIM, and YKL40 [5, 7, 9, 10, 26–31]. High expression of 2 or
more MES markers was found in 51 of 123 tumors (41%). Immunological
IHC-Based Subclassification of Newly Diagnosed GBMs
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markers, even though previously associated with the MES subclass, were omitted
from the current study [9]. Such markers can be used to assess activation or
infiltration of the immune system, but the tumor cells themselves mostly do not
express these markers. That renders TMA-based analysis unsuitable for these
markers.
The expression of neuronal markers in GBM and their potential role in
subclassification has been described [32–34]. The expression of neuronal markers
CHGA, NeuN, NEFL, and SYP was therefore also assessed in this study. High
expression of at least one of the neural markers was observed in 38 of 123 tumors
(31%), whereas 14 of these 38 tumors (37%) had coinciding expression of at least
two neuronal markers. Interestingly, mature neuronal cells, possibly healthy cells
trapped in the tumor, were also found to be present in several tumors.
For the Proliferative subclass Ki-67 and TOP2A were included as representative
markers [5]. Proliferative indices calculated from these stainings varied from 1.3%
to 88.2% for Ki-67, and from 0% to 97.4% for TOP2A. The correlation between
these proliferation markers was significant (Pearson r50.542, P,0.001).
Finally, three markers with reported variable association with different
subclasses were also included in the study. This concerned MET, previously
associated with the PN or the MES subclass [6, 35], GFAP, variably associated with
the PN, MES or Neural subclass [5, 33, 36], and PTEN, formerly mentioned to
associate with the PN or the MES subclass [5, 6, 35]. In our sample 18 tumors
(15%) displayed high MET expression, 26 of 123 tumors (21%) had high GFAP
expression, whereas PTEN was highly expressed by 29 of 123 tumors (24%).
Identification of three distinct subclasses through unsupervised
hierarchical clustering
The markers with differential and reproducible staining patterns were used to
cluster the complete set of 123 GBM samples. Unsupervised hierarchical clustering
of both markers and samples was performed, which resulted in the identification
of three distinct IHC/FISH-based clusters (Fig. 1). In the clustering process,
markers without discriminating power were excluded from the study at two
instances. The first instance for marker exclusion was when the markers did not
result in a differential staining pattern in the tumor set prior to clustering (DLL3
only). Second, markers that did not show any cluster association in the first
clustering attempt were removed from the study because they did not cluster with
their pre-designated cluster (FN1, NES, p53 and PDGFR-a, S3 Fig.). Markers were
also excluded in this step because they did not identify a specific group with high
expression of these markers (CHGA, Ki-67, NeuN, NEFL, OLIG2, SYP and
TOP2A). In the second clustering attempt NF1 and STAT3 showed very low
association with the MES markers and were excluded.
The first delineated cluster of tumors expressed markers characteristic of the
CLAS subtype (52 tumors, 42%; Fig. 1). Elevated EGFR protein expression was
observed in 51 of 52 tumors (98%), while EGFR amplification was diagnosed in
43 of 52 tumors (83%). Expression of EGFRvIII, indicative of the deletion of exon
IHC-Based Subclassification of Newly Diagnosed GBMs
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2 to exon 7 from the EGFR gene, was observed in 24 of 52 tumors (46%). All
EGFR markers were expressed significantly more in the CLAS group than in other
subclasses (P,0.001). Interestingly, a small group of 6 tumors exhibited EGFR
gene amplification but without protein overexpression.
The second cluster covered 6 tumors (5%) all expressing mutant IDH1 (R132H,
PN; Fig. 1). The IDH1R132H mutation was not found in the other clusters
(P,0.001). Besides this IDH1 mutation, high p53 expression was also detected
more frequently in the PN tumors. EGFR alterations and mesenchymal protein
expression were mutually exclusive with this cluster, while high expression of
neural markers was observed for half of the PN tumors. This cluster showed high
similarities to the PN subclass identified in previous studies [5, 6].
The third cluster (18 tumors, 15%), concerned tumors with high expression of
a combination of MES markers (MES; Fig. 1). A cluster was formed by PTEN,
VIM, CD44, GFAP, MET, and YKL40, most of them with differential expression
in the molecular subclasses (Fig. 1). In Fig. 2 the quantification of the expression
levels of MES markers is illustrated and compared over the identified subclasses. It
can be appreciated in this figure that only the MES markers PTEN, VIM and
YKL40 are able to discriminate specifically the MES group from the other
subclasses based on their median expression level. These markers are therefore
considered the most discriminative markers.
Fig. 1. Hierarchical clustering of 123 newly diagnosed GBMs reveals three distinct expression patterns. The expression patterns of 9 proteins and
the FISH status of EGFR, all positively or negatively associated with one of the predefined GBM subclasses (PN, CLAS, or MES), are depicted in the heat
map. Kendall’s tau coefficient is displayed as a similarity measure. This figure provides evidence for a differential IHC/FISH-based expression pattern by the
three subclasses.
doi:10.1371/journal.pone.0115687.g001
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Taken together, the IHC/FISH-based subclassification system was able to assign
predefined subclasses to 76 of 123 tumors included in the present study. The PN
and CLAS subclasses were characterized best by markers related to gene
mutations, gene amplifications or changes in protein expression, while the MES
was classified best by simultaneous high protein expression of several markers.
The previously described P and N subtypes were not detected as distinct subclasses
in this analysis.
PN/MES index
The feasibility of IHC/FISH-based PN and MES subclassification was also assessed
by the calculation of a so-called PN/MES index. The most discriminating markers
for the PN (IDH1R132H and p53) and MES (PTEN, VIM and YKL40) subclass
based on our results were used to calculate this index, in line with a previously
described method (Fig. 3A) [9]. A clearly distinctive PN group was identified on
the right side of the graph (PN/MES index.1, n53), and a MES group on the left
side of the graph (PN/MES index ,21, n575). The other 44 tumors were not
assigned any specific subclass (Fig. 3B).
Fig. 2. Marker validation graphs of the discriminating markers indicative of the MES subclass.Mean protein expression of CD44 (A), GFAP (B), MET
(C), PTEN (D), VIM (E) and PTEN (F) in the molecular subclasses is displayed. Values represent mean ¡ SEM; * P,0.05; ** P,0.01; *** P,0.001.
doi:10.1371/journal.pone.0115687.g002
IHC-Based Subclassification of Newly Diagnosed GBMs
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Fig. 3. IHC-based GBM subclassification into PN and MES subclasses based on two (PN) or three
(MES) representative stainings for each subclass. A. Representative photomicrographs (100x
magnification) for PN and MES GBM markers (PN: IDH1R132H and p53; MES: PTEN, VIM, and YKL40) are
shown. The recoding method of the stainings is also indicated. B. The distribution of the tumors based on the
PN/MES index is depicted here. Tumors with a PN/MES index greater than 1 were assigned the PN subclass
(blue box), while a PN/MES index smaller than 21 were assigned the MES subclass (red box). The
distribution of CLAS markers (EGFR expression level, EGFR amplification, and an EGFR mutation
[EGFRvIII]) was aligned with the index scores.
doi:10.1371/journal.pone.0115687.g003
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As this index was merely able to assign the PN and MES subclass to tumors and
other GBM subclasses are known to exist, a considerable amount of tumors was
on forehand expected to not be assigned any subclass. To assess in which region of
the graph these other subclasses were actually present, we next plotted
characteristic features of the CLAS subtype below the PN/MES index. Tumors
positive for CLAS features were distributed almost randomly along the graph with
a slight increase among the lower PN/MES indices, but they were completely
absent among the tumors characterized as PN in this analysis (Fig. 3B). Chi-
Square analyses pointed out that the distribution of CLAS features was statistically
not different among the classified groups in this analysis. This was the case for
EGFR expression (X2 [2, n5123] 52.93, P.0.05), EGFR amplification status (X2
[2, n5123] 55.29, P.0.05) and EGFRvIII expression (X2 [2, n5123] 51.01,
P.0.05).
IHC/FISH-based GBM subclasses are analogous to transcriptional
subclasses
To substantiate the relation of IHC/FISH-based PN and MES subclasses to
previously established transcriptional profiles [5], we performed qRT-PCR on
core samples from the PN and MES subclasses identified by the cluster analysis
and the PN/MES index. Four well-established PN and four MES genes [15] were
assessed to compare the gene expression of these genes in the IHC/FISH-based PN
and MES group (Fig. 4A and B, S2 Table). The mRNA expression ratios were
compared and 2 out of 4 PN genes were found to be expressed significantly higher
in the IHC/FISH-characterized PN group, while 3 of 4 MES genes were found to
be expressed significantly higher in the IHC/FISH-characterized MES group.
Secondly, a metagene score was calculated by a previously described method
[15]. An almost complete separation of the IHC/FISH-based PN samples from the
IHC/FISH-based MES samples was observed (Fig. 4C), but PN sample 5 was
found to transcriptionally have a more MES than PN profile. Taken together, this
implies that GBM samples assigned the PN subclass in the IHC/FISH study
corresponded to the established transcriptional PN subclass, and samples assigned
the MES subclass corresponded to the established transcriptional MES subclass.
Validation of IHC-based subclassification of newly diagnosed
GBMs
To further validate the potential of IHC-based subclassification of newly
diagnosed GBMs, an additional set of newly diagnosed GBMs was analyzed for the
expression of the markers that proved most useful in the analyses described in this
study. In this tumor set 2 tumors (5%) were positive for IDH1R132H. A total of 21
of 44 tumors (48%) presented with elevated EGFR expression, and only 1 of the
EGFR-positive tumors was positive for EGFRvIII expression. The expression of
MES markers PTEN, VIM and YKL40 was also assessed, allowing for the detection
of high expression of minimally 2 MES markers in 16 of 44 tumors (55%).
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By first assigning the PN subclass, then assessing the expression of CLAS
features to assign this subclass, and finally assigning the MES subclass based on
expression of MES markers, IHC-based subclasses were assigned to the validation
tumor set. Application of this scheme resulted in classification of 2 tumors (5%)
as PN, 21 tumors (48%) as CLAS and 7 tumors (16%) as MES. The assignment
rates for the subclasses are summarized in Table 2, where it can be observed that
the subclass assignment rates are highly similar in the training and validation
tumor set. A summary of the proposed assignment scheme is displayed in Fig. 5.
Fig. 4. Transctiption-based PN/MES gene expression profiles are in line with PN and MES IHC/FISH-
profiles. A. Expression ratios of mRNA of four PN genes (ASCL1, DLL3, NCAM1, and OLIG2) by core PN
and MES samples (n510 per subclass) are depicted. Significant higher expression of PN genes by core PN
samples was observed for two PN genes. The expression level by PN samples was set at 1. B. Expression
ratios of mRNA of four MES genes (CHI3L1, SERPINE, TGFB1, and TIMP1) by core PN and MES samples
(n510 per subclass) are depicted. Significant higher expression of MES genes by core MES genes was
observed for three of four MES genes. The expression level by MES samples was set at 1. (C) Heatmap of Z-
score corrected metagene scores, calculated on the basis of the expression of the PN and MES genes. Blue
shades represent a predominantly PN signature, red a MES signature, whereas white shades represent a
relatively balanced expression of both signatures as indicated in the figure. Values represent mean¡ SEM; *
P,0.05; ** P,0.01; *** P,0.001.
doi:10.1371/journal.pone.0115687.g004
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Discussion
In the current study, the feasibility of GBM subclassification by the use of tools
available in routine diagnostic settings was assessed. Three of the predefined
subclasses could be identified through an unsupervised hierarchical cluster
analysis of 10 pre-selected subclass-specific markers. Based on our results we
propose a minimal selection of markers required for IHC/FISH-based subtype
assignment. For the PN subclass IDH1R132H was found to be the only
discriminative marker, as the previously suggested markers PDGFR-a and p53 did
not show association with the PN subclass. A separate cluster characterized by
positivity for these two markers, which would resemble the IDH1-wild-type PN
tumors described more recently [37], were not identified either. The CLAS
subtype was characterized best by the IHC analysis for EGFR, and most of the
Table 2. Subclass assignment rates (%) per subclass in the training and validation tumor set.







Fig. 5. Proposed scheme of IHC-based subclass assignment in newly diagnosed GBMs. In the first step
the PN subtype is assigned on the basis of the R132H mutation in IDH1 . In the second step the CLAS
subtype is assigned on the basis of high EGFR expression. In the final step the MES subtype is assigned in
case two or more MES markers (PTEN, VIM and YKL40) are coincidently expressed at a high level.
doi:10.1371/journal.pone.0115687.g005
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CLAS tumors were also detected by the EGFRvIII IHC analysis. For MES subclass
assignment expression analyses for PTEN, VIM and YKL40 were found to be
superior to other MES markers. The application of multiple markers for the MES
subclass is necessary as the differential expression of these markers even within the
MES subclass can be appreciated in Fig. 1. Subclass-assignment by the novel
model we propose in this study (Fig. 5) was evaluated in an independent tumor
set leading to similar assignment rates as those observed in the training tumor set.
Besides selection of subclass-discriminative markers, the order of subclass
assignment is also important in the newly proposed model. As the defining
features of the PN signature are mutually exclusive with both the markers for the
CLAS and MES signature, the first subclass to be assigned should be the PN. In the
second step the CLAS subclass should be assigned, because the CLAS markers do
not appear in the pure MES subclass. In the final step the MES tumors can be
distinguished from tumors that cannot be assigned a specific subclass. We
emphasize the importance of the order of subclass assignment and the application
of multiple markers where appropriate, as tumors classified as CLAS here could
have easily been assigned the MES subclass in a different order of subclass
assignment. Coinciding expression of markers from several subclasses is known
not to affect IDH1-mutant PN tumors [15], but MES marker expression in CLAS
tumors does occur often [38]. The order of assignment proposed here will result
in more reliable and reproducible subclasses than would be the case when
employing previously suggested classification schemes [39–41]. These studies do
not describe an assignment scheme, do not include all the subclasses or do not
assess the order of subclass assignment.
The profiling through the 9-gene transcriptional PN/MES signature revealed
that IHC/FISH-based PN and MES signatures is comparable to the previously
established transcriptional signatures. All the differences in expression ratios of
subtype-matched genes were in the expected direction, although the actual
differences between these signatures are expected to be larger than reported here.
As only 6 tumors were characterized as PN in the cluster analysis (Fig. 1), the PN
group was complemented with tumors assigned the highest PN/MES indices
(Fig. 3B). One of these additional tumors transcriptionally showed a high MES
score (PN-10 in Fig. 4C). When looking at the protein expression profile of this
sample we also find that p53 expression was high, but high expression of multiple
MES markers like PTEN, VIM was also documented for this sample. The fact that
YKL40 was not highly expressed in this sample explains the more PN-like score
from the IHC-based PN/MES index. Application of the scheme proposed in Fig. 5
would have led to classification of this tumor as MES, underscoring the better
functionality of our proposed scheme in comparison to the previously described
IHC-based scheme for PN/MES subclassification [9].
The ratio of subclass assignment to tumors in this study (62%) was
considerably lower than in previous studies. In one study the complete patient
group was subclassified [5], and in the other study 85% of the tumor set was
subclassified (due to exclusion of 29 of 202 cases for reasons of lower similarity to
the identified subclasses) [6].
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At this point it cannot be ruled out that the PN tumors in our study sample
concern a small group of secondary GBMs, which did not cause symptoms in
lower-grade stages and were only recognized when they had progressed into the
GBM state. As secondary GBMs are histologically undistinguishable from primary
GBMs, it is impossible to diagnose this retrospectively. The defining character-
istics of the PN subtype are also frequently found in lower-grade gliomas or
secondary GBMs [42–44], and mutations in IDH1 and TP53 are normally found
in 70% and 50 to 60%, respectively, of lower-grade astrocytomas [43, 45–47].
Previous studies have not excluded lower-grade astrocytoma (grade III) from their
patient sample (21 of 76 tumors) [5], or the patient sample also included
secondary or recurrent GBMs (19 of 202 tumors) [6]. The rate of PN signature
occurrence amongst newly diagnosed GBMs thus seems debatable, and in
agreement with the suggestion by Nousmehr et al. [37], the exclusion of secondary
GBMs in our study resulted in a low assignment rate of the PN subclass. The
exclusion of secondary GBMs thus selected against the IDH1-mutant PN tumors,
also referred to as the G-CIMP-positive tumors, but the lack of markers for the G-
CIMP-negative PN tumors probably also contributed substantially to the lower
identification rate of the PN subclass [37, 48, 49].
The rate of assignment of the CLAS subtype in our study (42%) was slightly
higher than in other reports, whereas MES subclass assignment was in our study
considerably lower than in others [5, 6]. The MES subclass, contrary to the PN
subclass, is merely characterized by markers associated with de novo GBM. At least
in the case of the MES subclass inclusion criteria can thus not serve as an
argument for the ratio-difference of subclass assignment in our study. We propose
that the co-expression of multiple molecular signatures within tumors could
provide an explanation. Also in previous studies at the transcriptional level subsets
of tumors expressed markers characteristic of different subtypes, but in all these
cases the tumors possessed a dominant expression pattern for only one of the
subclasses [5, 6]. Tumors lacking dominant expression of a single molecular
signature, as was found for several tumors in our study, have not been described
in transcriptional studies before, possibly explaining the overall lower rate of
subclass assignment in this study. The finding of co-occurrence of multiple
molecular signatures is however supported by a recent report, which described the
co-existence of a PN-like subset of cells (PDGFRA amplification) besides a CLAS-
like subset of cells (EGFR amplification) within a single tumor, which was
determined through FISH-analysis [50]. Recognition of these mixed expression
patterns thus seems compromised at transcriptional level, but can be appreciated
by FISH and protein expression analyses.
Provided that approximately two thirds of tumors (76 of 123, 62%) were
subclassified into the three predefined subclasses in our study, the question how
useful subclassification for GBMs in fact is, could be posed. Clearly, a considerable
number of patients will not benefit from this subclassification effort, as they will
not be assigned any of the subtypes described in this report. We expect that the
benefit of the subclassification, however, lies in the fact that a restricted number of
patients (one of the subtypes) benefiting from a treatment could now be
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recognized in a clinical trial, while such survival advantages for a subset of patients
would likely have been missed in a non-stratified study. Given the enormous
heterogeneity of GBMs, identifying a subgroup of patients benefiting from a
treatment is probably a more realistic and expectable advancement than a uniform
cure for all GBM patients.
Conclusion
In conclusion, we were able to subclassify two-thirds of GBMs into predefined
molecular subclasses through the assessment of protein expression patterns. We
found that multiple signatures within the same tumor could be detected at protein
level, whereas this has not been described at the transcriptional level. The IHC-based
signatures identified in this study did however strongly resemble the established
transcriptional profiles. Subclassification of an independent tumor set resulted in
similar subclass assignment rates as were reported for the training tumor set.
The identification of more effective therapies from which only a part of GBM
patients benefits requires that tumor subclassification is incorporated in
preclinical and clinical studies. Incorporation of subclassification will also enable
development of therapies targeted at shared alterations within GBM subclasses.
Our suggested method, making use of techniques widely available in standard
diagnostic settings of pathology departments and by application of only a minimal
selection of markers, could provide very useful for subtyping of GBM samples of
individual patients in future studies.
Supporting Information
S1 Fig. Representative micrographs and scoring schemes of PN and MES
markers previously reported to have GBM subclass-associated expression
patterns. Micrographs were obtained at 100x magnification.
doi:10.1371/journal.pone.0115687.s001 (TIF)
S2 Fig. Representative micrographs and scoring schemes of CLAS, N and other
markers previously reported to have GBM subclass-associated expression
patterns. Micrographs were obtained at 100x magnification, FISH at 1000x
magnification.
doi:10.1371/journal.pone.0115687.s002 (TIF)
S3 Fig. Initial result of hierarchical clustering of 123 newly diagnosed GBMs
using 23 protein markers and 1 FISH analysis. Groups of tumors and clusters of
markers can be appreciated and are highlighted with black boxes. The P and N
markers are clustered in separate groups, but did not identify isolated groups of
tumors with high expression of these markers as primary characteristic. Kendall’s
tau coefficient is displayed as a similarity measure; *: Markers did not cluster with
their predesignated clusters.
doi:10.1371/journal.pone.0115687.s003 (TIF)
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S1 Table. Antigen retrieval methods and primary antibodies used for IHC and IF
analyses.
doi:10.1371/journal.pone.0115687.s004 (DOCX)
S2 Table. qRT-PCR data (n520) used to calculate the 9-gene PN/MES signature.
doi:10.1371/journal.pone.0115687.s005 (DOCX)
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